Back to All Combinations

NTRK Fusion + Any

Intermediate Prognosis
0.50% Prevalence A General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
NTRK Fusion
Recommended Treatments
Larotrectinib
Entrectinib
Treatments to Avoid

No specific contraindications noted

Key Statistics
0.50%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Rare but highly actionable. TRK inhibitors are tumor-agnostic approved.
Information

Category: General

Evidence Level: A

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.